Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Section for Preventive Cardiology
7 publications found
It's Time to Bury the "Smoker's Paradox"
Nicotine Tob Res, 21 (9), 1149-1150
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
J Am Coll Cardiol, 73 (23), 2961-2970
Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines for Norway
Eur Heart J, 40 (19), 1485-1487
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial
JAMA Cardiol, 4 (7), 613-619
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Circulation, 139 (12), 1483-1492
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
JAMA Cardiol, 4 (1), 59-63
BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial
Am J Clin Nutr (in press)